Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 137

Results For "EY"

3998 News Found

Mastek partners Innovaccer to transform value-based care and improve patient experience
Digitisation | October 22, 2024

Mastek partners Innovaccer to transform value-based care and improve patient experience

This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences


Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
News | October 21, 2024

Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test

Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI


Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets
Drug Approval | October 19, 2024

Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets

Granules now has a total of 67 ANDA approvals from the USFDA


Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study
News | October 19, 2024

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies


AstraZeneca advances science of infectious disease protection at IDWeek 2024
News | October 18, 2024

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19


MedGenome completes 10 years in genomics in India
News | October 18, 2024

MedGenome completes 10 years in genomics in India

MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all


Strides Pharma's CDMO arm OneSource raises Rs. 801 crore in pre-listing round
News | October 16, 2024

Strides Pharma's CDMO arm OneSource raises Rs. 801 crore in pre-listing round

The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion


Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease
News | October 14, 2024

Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease

The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease